World Heart Failure Drugs Market to Witness a CAGR of 9.1% During 2019-2025 – Dominated by Novartis, GlaxoSmithKline, AstraZeneca, Bayer, and Pfizer – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Heart Failure Drugs Market – Drivers, Restraints, Opportunities, Trends,
and Forecast up to 2025” report has been added to ResearchAndMarkets.com’s
offering.

The Global Heart Failure Drugs Market will grow at a CAGR of 9.1% during
the forecast period. The market has witnessed good growth in the past
few years and is sustaining due to the increasing elderly population and
increasing prevalence of cardiovascular diseases.

The growing market trend continues and is one of the progressively
accepted markets in many countries worldwide. Heart failure drugs
manufacturers are concentrating on the procurement of funds and
collaborating with universities to expand their R&D capabilities. Most
of the revenue is generated from the leading players in the market with
dominant sales from Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC,
Bayer AG, and Pfizer Inc.

According to analysis, North America leads the global heart failure
drugs market in 2018 followed by Europe. The US dominates the market
owing to the presence of a majority of the heart failure drugs
manufacturers in the region. However, the fastest growth rate is
anticipated to be in the APAC region due to the presence of large heart
failure patient population and the availability of a wide range of drugs.

By Drug Class:

• ACE Inhibitors
• Angiotensin Receptor Blockers
• Beta Blockers
• Diuretics
• Others

The diuretics segment occupied the largest share in 2018. The existing
guiding principle by the American College of Cardiology and the American
Heart Association recommends that diuretics should be directed at doses
adequate to attain optimum volume station and release cramming without
making an extremely fast drop in intravascular capacity.

By Regions:

• North America
• Europe
• APAC
• RoW

North America is dominant in the global heart failure drugs market
followed by Europe. The Duke University in North Carolina, US in
collaboration with National Heart, Lung, Blood Institute (NHLBI) and
Yale University is conducting phase III clinical trial TRANSFORM-HF a
large-scale, pragmatic, randomized, unblinded clinical effectiveness
study comparing torsemide versus furosemide as a treatment for heart
failure.

Competitive Analysis

The market is growing at a steady rate with a CAGR of 9.1% during the
forecast period 2019-2025. Merger and acquisition, product launches, and
strategic collaborations are some of the major strategies adopted by
market leaders to maintain their leadership position in the market. For
example, in February 2019, Amgen, Cytokinetics, and Servier initiated
the METEORIC-HF, the second phase III clinical trial of omecamtiv
mecarbil in patients with heart failure.

Universities and educational institutions are collaborating with the
market players to develop effective drugs for the treatment of heart
failure. For instance, Yale University in collaboration with Boehringer
Ingelheim is currently conducting a phase II clinical study; a minor
pilot proof of concept study to not only prove the existence but also
probe the mechanisms that are fundamental for the cardio-renal effects
of empagliflozin in patients with heart failure.

Key Vendors

• Novartis AG
• GlaxoSmithKline PLC
• AstraZeneca PLC
• Bayer AG
• Pfizer Inc.

Competitive Facts

• Sclnow Biotechnology Co., Ltd. is studying to access the safety and
  efficiency of human umbilical cord mesenchymal stem cells (hUC-MSC) in
  treating individuals suffering from heart failure. This treatment is
  in phase 1/2 currently.
• In January 2019, Sanofi and MyoKardia ended their heart disease drug
  collaboration.

Key Takeaways

• Understanding the potential market opportunity with precise market
  size and forecast data.
• A detailed market analysis focusing on the growth of heart failure
  drugs industry.
• Factors influencing the growth of the heart failure drugs market.
• In-depth competitive analysis of dominant and pureplay vendors.
• Prediction analysis of the heart failure drugs market in both
  developed and developing regions.
• Key insights related to major segments of the heart failure drugs
  market.
• Latest market trend analysis impacting the buying behaviour of the
  consumers.

Topics Covered

1 Industry Outlook

1.1 Industry Overview

1.2 Total Addressable Market

1.2.1 Industry Trends

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Market Definition

3.2 Segmented Addressable Market (SAM)

3.3 Industry Trends

3.4 Related Markets

3.4.1 Drug-Eluting Stents

3.4.2 Active Pharmaceutical Ingredients (APIs)

3.4.3 Over the Counter Drugs (OTC)

4 Market Outlook

4.1 Market Segmentation

4.2 Porter 5 (Five) Forces

5 Market Characteristics

5.1 Guidelines Summary

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 Increasing elderly population

5.2.1.2 Increasing incidence of cardiovascular devices across the globe

5.2.2 Restraints

5.2.2.1 Complex drug development process

5.2.2.2 Adverse effects of heart failure drugs

5.2.3 Opportunities

5.2.3.1 Market expansion opportunities in emerging nations

5.2.3.2 Novel heart failure medicines to fill the gap of unmet need in
treatment

5.2.4 DRO – Impact Analysis

5.3 Key Stakeholders

6 Technology Types: Market Size and Analysis

6.1 Overview

6.2 Beta Blockers

6.3 ACE Inhibitors

6.4 Angiotensin Receptor Blockers (ARBs)

6.5 Diuretic

6.6 Others

7 Regions: Market Size and Analysis

7.1 Overview

7.2 North America

7.2.1 Overview

7.2.2 US

7.2.3 Canada

7.3 Europe

7.3.1 Overview

7.3.2 UK

7.3.3 Germany

7.4 Asia Pacific

7.4.1 Overview

7.4.2 India

7.4.3 China

7.4.4 Japan

7.5 Rest of the World

7.5.1 Overview

7.5.2 Africa

7.5.3 Brazil

8 Competitive Landscape

9 Vendors Profile

9.1 Novartis AG

9.2 GlaxoSmithKline PLC

9.3 Bayer AG

9.4 Astra Zeneca PLC

9.5 Pfizer Inc.

10 Companies to Watch For

10.1 Merck & Co

10.2 Boehringer Ingelheim GmbH

10.3 Bristol-Myers Squibb

10.4 Mylan N.V.

10.5 Sanofi

10.6 Amgen Inc.

For more information about this report visit https://www.researchandmarkets.com/r/uf6yip

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs